ATRIUM Partners served as exclusive financial advisor to the shareholders of Ellipse in the sale to Syneron Candela

Ellipse develops, sells and markets laser and IPL based systems for non-invasive dermatological treatments with core competences within pigmented and vascular lesions. Ellipse is headquartered in Denmark and sells its products in more than 40 countries through a global network of distributors as well as subsidiaries in Spain, Germany and the UK. Revenue and EBITDA for the full year 2017 were EURm 12 and 2 respectively. The company was established in 1997 and previously owned by a private equity firm until it was acquired by management and private investors in 2010. Ellipse has since the management buy-out realized significant growth and built a leading market position within its core markets.

Syneron Candela is a leading global non-surgical aesthetic device company founded in 2000 with headquarters in Massachusetts, USA and major operations in Israel. In 2017, Syneron Candela was acquired and delisted from Nasdaq by APAX Partners in a transaction valued at approx. USDm 400.

With the acquisition of Ellipse, Syneron Candela will strengthen its market position and product portfolio, as well as expand its current distribution and sales network.

ATRIUM Partners

Advised in the sale of



Syneron Candela


MidCap Alliance